Clinical trial NCT00701649: Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension
Official title: A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hypertension
Keywords: mild essential hypertension
moderate essential hypertension
Lead sponsor: Cytos Biotechnology AG
Sponsor class: INDUSTRY
First posted: 2008-06-19
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: CYT006-AngQb is a vaccine that induces a B-cell mediated immune response characterized by the generation of specific antibodies (IgG and IgM) against Angiotensin II. The vaccine is administered by subcutaneous injection.

The objectives of the study are:

* To evaluate safety and tolerability of 5 s.c. injections of 300µg CYT006-AngQb with Alhydrogel™ in patients with mild to moderate essential hypertension (hypertension Grade I and II).
* To assess pharmacodynamic effects, i.e. anti-Ang II immune response and renin- angiotensin system (RAS) biomarkers.
* To explore the effect on blood pressure using ABPM.


Eligibility criteria: Inclusion Criteria:

* Patients with mild to moderate essential hypertension (Grade I and Grade II) with mean sitting office SBP =140-179 mmHg and/or mean sitting office DBP = 90-109 mmHg on 2 consecutive visits (screening and V1).
* Daytime blood pressure above threshold for definition of hypertension in the screening ABPM measurement (SBP \>135 mmHg).
* Patients without current antihypertensive therapy.
* Patients on antihypertensive therapy, which can be stopped.
* 18 to 69 years of age.
* Male patients, or female patients without childbearing potential .

Exclusion Criteria:

* Patients with "very high added risk" according to 2007 Guidelines for the Management of Arterial Hypertension (Journal of Hypertension, 2007, 25:1105-1187), i.e. those with:
* grade III hypertension (mean sitting office SBP ≥180mmHg and/or mean sitting DBP≥110mmHg)
* history or presence of established cardiovascular or renal disease:
* Ischemic stroke, cerebral hemorrhage, transient ischemic attack
* Myocardial infarction, angina pectoris, coronary re-vascularization, heart failure
* Peripheral artery disease
* Diabetic nephropathy
* Known autoimmune disease.
* Severe allergy.
* Pregnancy or breastfeeding.
* Women in childbearing age that are not surgically sterilized.
* Patients with a history or current positive test for HIV infection, AIDS, or other immunosuppressive disorders; hepatitis B or C.
* Current diagnosis or history of malignancy.
* Presence of suspicious lymphadenopathy or splenomegaly on physical examination.
* Drug or alcohol abuse within the past 2 years.
* Presence or history of relevant cardiovascular, renal, hepatic, pulmonary, endocrine, autoimmune, neurological and psychiatric disease as judged by the investigator.
* Any current or past disease or conditions (physical or mental) that would, in the opinion of the investigator, interfere with the study procedures or interpretation of the study data (e.g. workers in the night shift).
* Previous participation in a clinical trial with a Qb based vaccine.
* Use of an investigational drug within 3 months before enrolment, or planned use during the whole study period.
* Possible dependency of the patient on sponsor and/or investigator.
* Planned active immunization 2 weeks before or 2 weeks after any study medication vaccination.
* Donation or loss \>=400 mL of blood within 8 weeks prior to dosing or major surgery within past 2 months.

Primary outcomes:
measure: Adverse events: quality, quantity, severity
timeFrame: Throughout the study until week 48
Secondary outcomes:
measure: Change in daytime, nighttime and 24-hour ambulatory blood pressure from baseline
timeFrame: 24 hours
measure: Titer of IgG specific for angiotensin II
timeFrame: Throughout the study untill week 48
measure: Amount of RAS-Biomarkers (plasma renin concentration, angiotensin II, aldosterone)
timeFrame: 24 hours
Other outcomes:
Locations:
city: Mannheim
country: Germany
facility: CRS Mannheim
city: Mönchengladbach
country: Germany
facility: CRS Mönchengladbach
city: Basel
country: Switzerland
facility: University Hospital Basel
city: Bern
country: Switzerland
facility: Inselspital
city: Geneva
country: Switzerland
facility: Hopital Universitaire Geneve
city: Zürich
country: Switzerland
facility: Med Zentrum Römerhof
Study officials:
References: